The safety and effectiveness of newer antiepileptics: A comparative postmarketing cohort study

Journal of Clinical Pharmacology

Volumn 45, Issue 4, 2005, Pages 385-393

  Acharya, Nayan V ^a,b   Pickering, Ruth M ^c   Wilton, Lynda W ^a   Shakir, Saad A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b University of Southampton ^*

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Efficacy; Gabapentin; Lamotrigine; Newer antiepileptic drugs; Postmarketing surveillance; Prescription event monitoring; Safety; Treatment failure; Vigabatrin

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; NEW DRUG; VIGABATRIN;

ADULT; AGGRESSION; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; COHORT ANALYSIS; CONFUSION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPILEPSY; FEMALE; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUROTOXICITY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RASH; SEDATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; ANTICONVULSANTS; COHORT STUDIES; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT FAILURE;

EID: 17044413349     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004273678     Document Type: Article

References (27)

1. Cockerell OC, Johnson AI, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346:140-144.
2. Chadwick D. Standard approach to antiepileptic drug treatment in the United Kingdom. Epilepsia. 1994;35(suppl 4):11-18.
3. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf. 1993;9:156-184.
4. Marson AG, Kadir ZA, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J. 1996;313:1169-1174.
5. Chadwick DW for the Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet. 1999;354:13-19.
6. Mann RD. Prescription-event monitoring recent progress and future horizons. Br J Clin Pharmacol. 1998;46:195-201.
7. Layton D, Pearce GL, Shakir SAW. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001;24:703-713.
8. Craig-McFeely PM, Acharya NV, Shakir SAW. Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol. 2001;57:313-320.
9. Heeley E, Riley J, Layton D, Wilton L, Shakir S. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;356:1872-1873.
10. Central Office for Research Ethics Committees. General guidance for researchers: Multi-Centre Research Ethics Committee, Appendix C, guidance notes. Available at: http://www.corec.org.uk/wordDocs/ guideNotes.doc. Accessed March 10, 2003.
11. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997;38:881-886.
12. Wilton LV, Stephens BS, Mann RD. Interim report on the incidence of visual field defects in patients on long term vigabatrin therapy. Pharmacoepidemiol Drug Saf. 1999;8:S(9)-S(14).
13. Wilton LV, Shakir SAW. A post-marketing surveillance study of gabapentin as add-on therapy for 3100 patients in England. Epilepsia. 2002;43:983-992.
14. Stata Statistical Software: Release 6.0. College Station, Tex: Stata Corporation; 1999.
15. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia. 1999;405:590-600.
16. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345:476-479.
17. Beggs PW, Clark DW, Williams SM, Coulter DM. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). Br J Clin Pharmacol. 1999;47:99-104.
18. Kubota K, Kawabe E, Hinotsu S, Hamada C, Ohashi Y, Kurokawa K. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemies. Eur J Clin Pharmacol. 2001;56:831-838.
19. Shakir SAW, Wilton LV. Drug safety research unit and pharmacoepidemiology. Int J Pharm Med. 2000;14:1-4.
20. US Gabapentin Study Group. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43:2292-2298.
21. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990;335:1114-1147.
22. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 1998;18:281-296.
23. Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S45-S51.
24. Kalvianinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs. 2001;15:217-230.
25. Wilton LV, Stephens MD, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. Br Med J. 1999;319:1165-1166.
26. Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia. 1991;32(suppl 2):S17-S21.
27. Shakir SAW. PEM in the UK. In: Mann R, Andrews E, eds. Pharmacovigilance. Chichester, UK: John Wiley; 2002:333-344.